Emergent BioSolutions, a specialty biopharmaceutical company, will launch a military-grade auto-injector device, known as Emergard, designed for intramuscular self-injection of emergency response medical treatments that can address exposure to certain chemical agents and emerging threats.

Emergent acquired rights to the device, formerly known as PC-2M, through an exclusive worldwide license agreement with Pharma Consult Ges.m.b.H, an injectable device producer from Austria. Emergard is designed to be transported, stored, and operated in a military environment and penetrate successful injection through chemical protective gear.

Emergent anticipates making its first deliveries of Emergard in limited quantities to interested markets outside the US in the fourth quarter 2015. The device is currently not marketed in the US although Emergent intends to pursue approval from the US Food and Drug Administration.

Source: Emergent BioSolutions